You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

14 Results
Guidelines and Advice
Status: Archived
ID: 22-2-1
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-2
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-3
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-4
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-5
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-6
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-7
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-8
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-9
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-10
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-M
Jun 2014
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - In Combination with Lenalidomide and Dexamethasone for Previously Untreated Multiple Myeloma Without Intent for Stem Cell Transplantation
ODB Limited Use
    lenalidomide - For the treatment of patients with multiple myeloma, who are deemed to be lenalidomide sensitive, and/or have not experienced progression while on a lenalidomide-based regimen in the treatment or maintenance setting, according to clinical criteria
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
bortezomib (PDRP prior authorization),
lenalidomide,
dexamethasone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2025

Pages